Gilead Sciences returns 11.43% annually over 20 years
Gilead Sciences has outperformed the market with an average annual return of 11.43% over the last two decades. The company's current market capitalization stands at $164.76 billion. A hypothetical $100 investment made 20 years ago would now be worth $854.46.
*this image is generated using AI for illustrative purposes only.
Gilead Sciences has generated an average annual return of 11.43% over the past 20 years, outperforming the market by 2.19% on an annualized basis. The biopharmaceutical company currently commands a market capitalization of $164.76 billion. This long-term performance highlights the impact of compounded returns on equity growth over extended periods.
Investment Growth Analysis
If an investor had purchased $100 worth of Gilead Sciences stock 20 years ago, that investment would be valued at $854.46 today. This calculation is based on a current share price of $132.70. The substantial growth underscores the potential benefits of long-term holding strategies in the healthcare sector.
Key Performance Metrics
The following table summarizes the financial performance data for Gilead Sciences over the specified period:
| Metric | Value |
|---|---|
| Average Annual Return | 11.43% |
| Market Outperformance | 2.19% |
| Current Market Capitalization | $164.76 billion |
| Current Share Price | $132.70 |
| Value of $100 Invested 20 Years Ago | $854.46 |
The data illustrates how consistent returns can significantly multiply initial capital over time, emphasizing the importance of compounded growth in investment portfolios.
Can Gilead maintain its historical 11.43% annual return given current patent cliffs and pipeline risks?
How might upcoming regulatory changes impact the company's ability to sustain market outperformance?
What role will mergers and acquisitions play in driving future growth for Gilead?
15
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
